drugset / Trial / NCT00109239

A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer

NCT00109239 ↗

Phase 3 Completed Genentech, Inc.
RandomizedOpen-labelTreatment

Summary

This Phase III, multicenter, randomized, active-controlled, open-label trial is designed to evaluate the efficacy, safety, and pharmacokinetics of rhuMAb VEGF when combined with capecitabine compared with capecitabine alone in subjects with previously treated metastatic breast cancer.

Timeline

Start
2000-11
Primary completion
—
Completion
2002-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — —

Indications